Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS
· Delayed Price · Currency is USD
2.271
-0.029 (-1.27%)
Jul 3, 2025, 12:44 PM EDT
Medexus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 108.33 | 113.05 | 108.1 | 76.7 | 79.66 | Upgrade
| |
Revenue Growth (YoY) | -4.18% | 4.59% | 40.93% | -3.72% | 43.52% | Upgrade
|
Cost of Revenue | 44.82 | 47.99 | 42.33 | 33.03 | 32.18 | Upgrade
|
Gross Profit | 63.51 | 65.07 | 65.77 | 43.67 | 47.48 | Upgrade
|
Selling, General & Admin | 43.18 | 44.87 | 48.25 | 44.03 | 36.17 | Upgrade
|
Research & Development | 1.23 | 1.61 | 2.94 | 5.87 | 4.6 | Upgrade
|
Operating Expenses | 51.59 | 52.28 | 57.28 | 56.05 | 46.75 | Upgrade
|
Operating Income | 11.92 | 12.79 | 8.49 | -12.38 | 0.73 | Upgrade
|
Interest Expense | -8.2 | -13.36 | -13.61 | -12.22 | -9.82 | Upgrade
|
Currency Exchange Gain (Loss) | - | - | -1.69 | -0.15 | 1.99 | Upgrade
|
Other Non Operating Income (Expenses) | 1.41 | 2.68 | 2.64 | 23.55 | -22.3 | Upgrade
|
EBT Excluding Unusual Items | 5.14 | 2.1 | -4.17 | -1.2 | -29.39 | Upgrade
|
Merger & Restructuring Charges | -0.9 | -1.11 | -0.88 | -0.87 | -2.11 | Upgrade
|
Asset Writedown | -2.8 | -0.89 | - | -1.75 | - | Upgrade
|
Pretax Income | 1.44 | 0.11 | -5.04 | -3.82 | -31.5 | Upgrade
|
Income Tax Expense | -0.81 | 0.32 | -6.26 | -0.94 | -3.24 | Upgrade
|
Net Income | 2.25 | -0.21 | 1.22 | -2.88 | -28.26 | Upgrade
|
Net Income to Common | 2.25 | -0.21 | 1.22 | -2.88 | -28.26 | Upgrade
|
Shares Outstanding (Basic) | 26 | 22 | 20 | 19 | 15 | Upgrade
|
Shares Outstanding (Diluted) | 27 | 22 | 21 | 20 | 15 | Upgrade
|
Shares Change (YoY) | 18.76% | 8.76% | 3.36% | 30.65% | 5.83% | Upgrade
|
EPS (Basic) | 0.09 | -0.01 | 0.06 | -0.15 | -1.86 | Upgrade
|
EPS (Diluted) | 0.08 | -0.01 | 0.06 | -0.15 | -1.86 | Upgrade
|
Free Cash Flow | 23.85 | 18.66 | -1.51 | -1.28 | 4.92 | Upgrade
|
Free Cash Flow Per Share | 0.90 | 0.84 | -0.07 | -0.06 | 0.32 | Upgrade
|
Gross Margin | 58.62% | 57.56% | 60.84% | 56.94% | 59.60% | Upgrade
|
Operating Margin | 11.00% | 11.31% | 7.85% | -16.13% | 0.92% | Upgrade
|
Profit Margin | 2.07% | -0.19% | 1.13% | -3.75% | -35.48% | Upgrade
|
Free Cash Flow Margin | 22.02% | 16.51% | -1.39% | -1.67% | 6.18% | Upgrade
|
EBITDA | 18.94 | 18.44 | 14.37 | -6.46 | 6.35 | Upgrade
|
EBITDA Margin | 17.48% | 16.31% | 13.30% | -8.42% | 7.98% | Upgrade
|
D&A For EBITDA | 7.02 | 5.66 | 5.88 | 5.92 | 5.62 | Upgrade
|
EBIT | 11.92 | 12.79 | 8.49 | -12.38 | 0.73 | Upgrade
|
EBIT Margin | 11.00% | 11.31% | 7.85% | -16.13% | 0.92% | Upgrade
|
Effective Tax Rate | - | 301.89% | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.